Dabigatran etexilate patent?

What patents cover dabigatran etexilate?
The primary patents covering the drug’s active ingredient, dabigatran etexilate, were granted to Pfizer and its partners in the early 2000s. Key U.S. patents include US 7,058,207 (covering the molecule itself) and US 7,181,302 (covering the salt formulation). These patents granted the company exclusive rights to manufacture and sell the drug for a set period.

When did the original patents expire?
The core patents on dabigatran etexilate expired between 2014 and 2018, depending on jurisdiction. In the United States, the last of the original patents expired in 2016, after which the product entered a period of generic competition under the 505(b)(2) pathway.

Can generic manufacturers enter the market now?
Yes. Following the patent expirations, multiple generic versions were approved by the FDA and are sold under the generic name dabigatran. Generic entry began in late 2016, and several biosimilar‑style formulations have since been marketed.

Are there ongoing patent disputes or challenges?
Some secondary patents, covering formulation improvements and specific delivery methods, have been the subject of litigation. In 2018, a U.S. District Court ruling invalidated a secondary patent that Pfizer had used to block a generic entrant, reinforcing the broader generic availability of dabigatran.

Who currently owns the remaining patents?
Pfizer retains a handful of secondary patents, but most of the core patents are now public domain. The company’s portfolio largely focuses on complementary products, such as anticoagulant combinations, rather than on dabigatran itself.

How does the patent landscape affect pricing?
With the primary patents expired, price competition has driven the cost of dabigatran down significantly. Generic versions are typically 70–90 % cheaper than the original Pradaxa brand, although price differences vary by insurer and region.

What is the current regulatory status?
The FDA continues to approve new indications for dabigatran, including use in atrial fibrillation and venous thromboembolism. The drug remains under post‑marketing surveillance for rare bleeding events and drug interactions.

When can patients expect further generic competition?
Additional generics are likely to appear as secondary patents expire or are invalidated, but the market is already mature. New entrants usually arise a year or two after a patent lapses.

Where can I find the most up‑to‑date patent data?
DrugPatentWatch.com tracks all relevant filings and legal status changes for dabigatran etexilate. Visit the site for detailed timelines and legal documents. [1]